State Coverage and Reimbursement of Antiobesity Medications in Medicaid.
作者信息
Liu Benjamin Y, Rome Benjamin N
机构信息
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.
出版信息
JAMA. 2024 Apr 9;331(14):1230-1232. doi: 10.1001/jama.2024.3073.
Abstract
摘要
相似文献
1
State Coverage and Reimbursement of Antiobesity Medications in Medicaid.
JAMA. 2024 Apr 9;331(14):1230-1232. doi: 10.1001/jama.2024.3073.
2
GLP-1 Medication Use for Type 2 Diabetes Has Soared.
JAMA. 2024 Sep 24;332(12):952-953. doi: 10.1001/jama.2024.18219.
3
How Will Repealing the ACA Affect Medicaid? Impact on Health Care Coverage, Delivery, and Payment.
Issue Brief (Commonw Fund). 2017 Mar;8:1-10.
4
Medicaid and indigent care issue brief: Medicaid: provider reimbursement.
Issue Brief Health Policy Track Serv. 2000 Jun 1:1-15.
5
Are You Following Your Reimbursement "Playbook"?
Adv Skin Wound Care. 2019 Jul;32(7):295-296. doi: 10.1097/01.ASW.0000559955.31282.fd.
6
Medicaid and indigent care issue brief: Medicaid: provider reimbursement.
Issue Brief Health Policy Track Serv. 2000 Jul 1:1-15.
7
Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2004.
Issue Brief Health Policy Track Serv. 2004 Dec 31:1-24.
8
State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Value Health. 2018 Jun;21(6):692-697. doi: 10.1016/j.jval.2017.09.011. Epub 2017 Nov 7.
9
Changes to Medicare, Medicaid Coverage Could Cause Thousands of Deaths.
JAMA. 2024 Jun 11;331(22):1884. doi: 10.1001/jama.2024.8426.
10
Dependent Coverage under the ACA and Medicaid Coverage for Childbirth.
N Engl J Med. 2016 Jan 14;374(2):194-6. doi: 10.1056/NEJMc1507847.
引用本文的文献
1
Spending, utilization, and price trends for anti-obesity medications in U.S. Medicaid programs: an empirical analysis from 1999 to 2023.
Front Med (Lausanne). 2025 Jul 16;12:1537181. doi: 10.3389/fmed.2025.1537181. eCollection 2025.
2
Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US.
J Comp Eff Res. 2025 Sep;14(9):e250083. doi: 10.57264/cer-2025-0083. Epub 2025 Jul 11.
3
Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?
Front Endocrinol (Lausanne). 2025 Jun 18;16:1569468. doi: 10.3389/fendo.2025.1569468. eCollection 2025.
4
Comparing clinical practice habits among obesity medicine physicians by patient, physician and clinic factors.
Obes Pillars. 2025 Jan 7;13:100157. doi: 10.1016/j.obpill.2025.100157. eCollection 2025 Mar.
5
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.
JAMA Netw Open. 2025 Jan 2;8(1):e2457349. doi: 10.1001/jamanetworkopen.2024.57349.
6
Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
J Pharm Policy Pract. 2024 Dec 24;18(1):2441220. doi: 10.1080/20523211.2024.2441220. eCollection 2025.
7
Anti-obesity medication patients' self-reported food savings versus the cost of such medicines.
Int J Obes (Lond). 2025 Mar;49(3):532-535. doi: 10.1038/s41366-024-01708-y. Epub 2024 Dec 29.
8
Longitudinal policy surveillance of state obesity legislation in California, 1999-2020.
BMC Public Health. 2024 Nov 6;24(1):3064. doi: 10.1186/s12889-024-20557-y.
9
Applying an Equity Lens to Pediatric Obesity: Clinical, Environmental, and Policy Considerations for Clinicians.
Pediatr Clin North Am. 2024 Oct;71(5):805-818. doi: 10.1016/j.pcl.2024.07.001. Epub 2024 Aug 8.
10
Navigating coverage: A qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication.
Obes Pillars. 2024 Jul 22;11:100120. doi: 10.1016/j.obpill.2024.100120. eCollection 2024 Sep.
Zotero 插件